Cargando…

Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients

BACKGROUND: The angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension (HT). Whether the use of these drugs increases the infectivity of novel coronavirus and results in an additional risk for morbidity and mortal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baslilar, Seyma, Saylan, Bengu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital and Research Centre 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497007/ https://www.ncbi.nlm.nih.gov/pubmed/34618609 http://dx.doi.org/10.5144/0256-4947.2021.268

Ejemplares similares

Comparative assessment of outcomes of smoking cessation therapies and role of free medications in successful long-term abstinence
por: Saylan, Bengu, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs
por: Abdullah, Muhammad, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021)

Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
por: Tian, Ci, et al.
Publicado: (2021)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Response surface analyses of antihypertensive effects of angiotensin receptor blockers and amlodipine or hydrochlorothiazide combination therapy in patients with essential hypertension
por: Cho, Minhee, et al.
Publicado: (2023)

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
por: Lai, Chih-Cheng, et al.
Publicado: (2018)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
por: Jin, Kyubok, et al.
Publicado: (2013)

Why angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are not prescribed in the management of hypertension among hemodialysis patients in India
por: Mateti, Uday Venkat, et al.
Publicado: (2014)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension
por: Li, Mingfei, et al.
Publicado: (2021)

Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers and Mortality in Patients with Hypertension Hospitalized with COVID-19
por: Abedtash, Amirhossein, et al.
Publicado: (2021)

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
por: Rudolph, Ulrike Maria, et al.
Publicado: (2020)

Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients
por: Ayten, Omer, et al.
Publicado: (2020)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021)

Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese
por: Gong, Hong-Tao, et al.
Publicado: (2019)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Ku, Elaine, et al.
Publicado: (2018)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
por: Wu, Hon-Yen, et al.
Publicado: (2013)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
por: Khera, Rohan, et al.
Publicado: (2021)

The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients: Is there a room for vitamin D?
por: Sukkarieh, Hatouf H., et al.
Publicado: (2020)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Impact of Angiotensin Receptor Blockers Use on In-Hospital Mortality in Community-Acquired Pneumonia Patients with Hypertension
por: Chen, Dawei, et al.
Publicado: (2023)

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
por: Zhang, Peng, et al.
Publicado: (2020)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension
por: van Sloten, Thomas T, et al.
Publicado: (2022)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
por: Alsaeed, Abdulghani
Publicado: (2021)

Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
por: Jawad, Ali S.
Publicado: (2020)

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
por: Khera, Rohan, et al.
Publicado: (2020)

Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction
por: Lee, Jae-Geun, et al.
Publicado: (2023)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_16ham1mbuocqt253fa0igclr3j